Allegion plc

The full register, from 13F filings

The Register tab above is hand research: a dozen holders, each traced to the filing it came from. This asks the same question of the whole market for the quarter ended 31-mar-2026, where 749 managers reported a position. Broad where the research is deep, and shallow in the ways a 13F always is.

Built from 13F filings, which report US listed, long, US custodied positions only. A register from this source is a floor rather than a level: a holder's true position can be far larger, as BlackRock's ASML stake shows at 1.28m shares in a 13F against 26.3m in its 13G/A. Holdings held through derivatives, outside US custody, or below a manager's reporting obligation do not appear. Where a holder is marked as a family, its total sums several separate filing entities and describes something no single filing describes; the constituent entities and their share counts are listed so the total can be checked. That roll-up can legitimately exceed the family's own Schedule 13G, because a 13G is filed by one legal entity: Vanguard reports Alphabet through ten advisory entities, and The Vanguard Group Inc itself reported zero after its January 2026 disaggregation.

What a reader needs to know to read these numbers

• Holdings side: searched the latest 10-Q (period 30 Jun 2026, filed 23 Jul 2026, the newest filing on record) and the latest 10-K (fiscal year ended 31 Dec 2025, filed 17 Feb 2026) for 'equity method', 'equity investment', 'joint venture', 'non-marketable', 'unconsolidated', 'minority interest', 'investment in', 'noncontrolling', 'venture', 'variable interest entity' and 'retained interest'. The 10-Q (the freshest document) had NO hits at all for 'equity method', 'equity investment', 'non-marketable', 'unconsolidated', 'joint venture' or 'minority interest': its only relevant disclosure is a combined $66.6 million / $66.8 million (30 Jun 2026 / 31 Dec 2025) balance of 'investments in debt and equity securities without readily determinable fair values', with no ownership percentage, share count, or investee name given. The 10-K discloses two further combined, unnamed buckets: 'Investments in equity method affiliates totaled $15.5 million and $13.7 million as of December 31, 2025 and 2024, respectively' (the Company applies the equity method when it can exercise significant influence, without a controlling interest, over start-up or development-stage investees) and 'Investments in debt and equity securities not accounted for under the equity method... totaled $66.8 million and $66.9 million as of December 31, 2025 and 2024, respectively.' No investee is named anywhere in either filing (searched 'affiliate', 'investee', and every current Allegion product brand name (Schlage, CISA, LCN, SimonsVoss, Von Duprin, Falcon etc.) which returned only wholly owned-subsidiary brand mentions, not investees). Per the project's rule against assigning a combined balance to one investee, none of these three buckets is sized to any individual holding; each combined figure is recorded here in this note rather than as a holdings row. Exhibit 21 (list of subsidiaries, filed with the 10-K) was checked and is a bare name list of Allegion's own wholly owned operating subsidiaries (Schlage Lock Company LLC, Von Duprin LLC, CISA S.p.A., SimonsVoss Technologies GmbH and similar entities across many jurisdictions) with NO ownership-percentage column and no minority-stake or joint-venture entries: a genuine negative, not evidence of a wrong search location. Noncontrolling interests reported in Allegion's own consolidated statements ($0.2 million in 2023, zero in 2024 and 2025) are OTHER parties' minority stakes in Allegion's controlled subsidiaries, the reverse direction from what this file records, and are excluded for that reason. Conclusion: holdings is a legitimate empty array. Allegion runs a small, undisclosed equity/venture-investment program (equity-method affiliates plus other minority equity/debt securities, roughly $82 million combined at 30 Jun 2026) but discloses no investee by name, share count, or ownership percentage in any filing checked, so no row can be sourced without violating the project's combined-balance rule.
• Capital Group checked across all six registrants per the project's TransDigm precedent and found to hold NOTHING in Allegion as of Q2 2026: Capital World Investors CIK 0001422849, Capital International Investors CIK 0001562230, Capital Research Global Investors CIK 0001422848, Capital International, Inc./CA/ CIK 0000895213, Capital International Ltd /CA/ CIK 0001065350, and Capital International Sarl CIK 0001065349 (all filed 13F-HR 12 Aug 2026 for period 30 Jun 2026). None of the six has a row matching CUSIP G0176J109. A fragment search for 'ALLEG' on the two registrants that returned any match hit only Allegro Microsystems Inc (CUSIP 01749D105) and, on one registrant, Allegiant Travel Co (CUSIP 01748X102), confirming these are name collisions and not Allegion. No row recorded; this is a genuine negative across all six registrants.
• data/registers/ALLE.json (a 31 Mar 2026 13F snapshot) was used ONLY to enumerate the Vanguard family's 8 filing entities and to identify other sizable 13F holders worth checking (it lists Vanguard, BlackRock, Boston Partners, State Street, Kayne Anderson Rudnick, Geode, MFS, Invesco, Brown Advisory and others, but carries NO Capital Group entity and NO T. Rowe Price entity at all, consistent with the negative findings above and with the project's warning that this snapshot can be incomplete). Every SHARE FIGURE in this file was independently re-fetched from each holder's own Q2 2026 (30 Jun 2026) 13F-HR filing rather than taken from that snapshot.
• Implied per-share price check: dividing each institutional 13F row's dollar value by its share count gives approximately $140.05 to $140.50 per share across all 10 institutional register rows (Vanguard's 8 entities, BlackRock, Boston Partners, State Street, Geode, Invesco, Morgan Stanley, FMR, Northern Trust, T. Rowe Price Associates), all dated 30 Jun 2026: a tight, independent cross-check that every row is the same instrument (CUSIP G0176J109, Allegion plc ordinary shares) at the same date, and that the T. Rowe Price 'values in thousands' conversion (from $18,048 thousand to $18,048,000) was applied correctly. This is well below the live 19 Aug 2026 quote of $162.32 used for market_cap_usd, consistent with roughly seven weeks of price movement between the two dates (52-week range $125.00 to $183.11 per the same Nasdaq quote page).
• Self-gate computed from this final file: 11 register rows, no row rolls up into another (the directors/officers proxy aggregate has no individually broken-out member rows in this file, since every named director and NEO held under 1% and only the group total is disclosed), so every row counts at full value per the chart's own arithmetic. Total shares: 11,473,520 (Vanguard) + 6,806,953 (BlackRock) + 4,645,278 (Boston Partners) + 4,344,088 (State Street) + 2,895,905 (Geode) + 2,292,541 (Invesco) + 1,598,055 (Morgan Stanley) + 1,342,197 (FMR/Fidelity) + 872,670 (Northern Trust) + 128,461 (T. Rowe Price) + 553,140 (directors and officers) = 36,952,808 shares. Against shares_outstanding of 85,036,786, that is 43.46% of the company. This sits within the brief's expected 25% to 45% band and was checked for the three usual causes: no holder appears twice (each institutional row is a single named filer or an explicitly summed family with no overlap with any other row; Capital Group was checked across all six registrants and holds zero, so it is a note, not a row), every institutional row is the same CUSIP G0176J109 common/ordinary stock read directly from that holder's own Q2 2026 13F-HR, and the implied-price check above shows all 10 institutional rows agree to within a few cents per share.
• Allegion plc is incorporated in Ireland (registered office: Unit No. 233, The Capel Building, Mary's Abbey, Dublin 7, D07 X324, Ireland) but reports in USD and files as a US domestic filer (10-K/10-Q/DEF 14A rather than 20-F/6-K), consistent with the brief's expectation. Two effects of the Irish incorporation observed while researching this file: (1) the DEF 14A calls the equity 'ordinary shares' throughout rather than 'common stock', and Allegion's own 13F CUSIP records list the instrument as 'ORD SHS'; the 'interested shareholder' change-in-control definition in the proxy is expressed under Irish law rather than a US state anti-takeover statute (referencing 30% or more of combined voting power). (2) The 2026 DEF 14A's own 5%-owner table is built entirely from Schedule 13G filings (BlackRock and Boston Partners only, both stale as of 31 Mar 2025) with no independent proxy-level disclosure of Vanguard, which the Q2 2026 13F-HR sweep shows holds roughly 13.5% in aggregate; nothing here indicates the Irish incorporation itself changes who must file a 13D/G against a NYSE-listed, SEC-reporting Irish plc, and the gap looks like the same subsidiary-level 13G-threshold pattern seen at other (US-incorporated) companies in this project, not an Ireland-specific effect.
• Market cap uses a live intraday quote (Nasdaq API, $162.32, 19 Aug 2026 3:52pm ET) multiplied by the 20 Jul 2026 cover-page share count of 85,036,786; the two dates are about four weeks apart because no single source carries both a live price and a current share count on the same day. Disclosed rather than treated as precise.